The latest price target for Neurocrine Biosciences (NASDAQ:NBIX) was reported by Goldman Sachs on June 2, 2026. The analyst firm set a price target for $213.00 expecting NBIX to rise to within 12 months (a possible 22.06% upside). 65 analyst firms have reported ratings in the last year.

The latest analyst rating for Neurocrine Biosciences (NASDAQ:NBIX) was provided by Goldman Sachs, and Neurocrine Biosciences their buy rating.

The last upgrade for Neurocrine Biosciences Inc happened on April 15, 2025 when Needham raised their price target to $138. Needham previously had a hold for Neurocrine Biosciences Inc.

The last downgrade for Neurocrine Biosciences Inc happened on January 8, 2026 when Morgan Stanley changed their price target from $173 to $175 for Neurocrine Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurocrine Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurocrine Biosciences was filed on June 2, 2026 so you should expect the next rating to be made available sometime around June 2, 2027.

While ratings are subjective and will change, the latest Neurocrine Biosciences (NBIX) rating was a with a price target of $0.00 to $213.00. The current price Neurocrine Biosciences (NBIX) is trading at is $174.50, which is within the analyst’s predicted range.